Pfizer Inc. (NYSE:PFE) shares, rose in value, with the stock price down by -2.09% to the previous day’s close as strong demand from buyers drove the stock to $26.65.
Actively observing the price movement in the last trading, the stock closed the session at $27.22. The value of beta (5-year monthly) was 0.57 whereas the PE ratio was 74.15 over 12-month period. Referring to stock’s 52-week performance, its high was $42.22, and the low was $25.61. On the whole, PFE has fluctuated by 2.19% over the past month.
With the market capitalization of Pfizer Inc. currently standing at about $150.49 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 01, 2024. The company’s Forward Dividend Ratio is 1.65, with its dividend yield at 6.19%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.54, which is expected to increase to $0.62 for fiscal year $2.2 and then to about $2.76 by fiscal year 2025. Data indicates that the EPS growth is expected to be 28.70% in 2025, while the next year’s EPS growth is forecast to be 25.50%.
Analysts have estimated the company’s revenue for the quarter at $13.19 billion, with a low estimate of $11.84 billion and a high estimate of $15.29 billion. According to the average forecast, sales growth in current quarter could jump down -20.50%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $55.7 billion, representing an increase of 2.50% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that PFE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PFE currently trading nearly -3.61% and -2.80% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.59, while the 7-day volatility ratio is showing 1.73% which for the 30-day chart, stands at 1.81%. Furthermore, Pfizer Inc. (PFE)’s beta value is 0.61, and its average true range (ATR) is 0.52.
A comparison of Pfizer Inc. (PFE) with its peers suggests the former has fared considerably weaker in the market. PFE showed an intraday change of -2.09% in last session, and over the past year, it shrunk by -35.55%%.
Data on historical trading for Pfizer Inc. (NYSE:PFE) indicates that the trading volumes over the past 10 days have averaged 33.28 million and over the past 3 months, they’ve averaged 43.05 million. According to company’s latest data on outstanding shares, there are 5.65 billion shares outstanding.
Nearly 0.04% of Pfizer Inc.’s shares belong to company insiders and institutional investors own 70.12% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 71.65 million shares as on Mar 15, 2024, resulting in a short ratio of 1.5. According to the data, the short interest in Pfizer Inc. (PFE) stood at 1.27% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 60.68 million. The stock has fallen by -7.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PFE stock heading into the next quarter.
